Pearl Therapeutics turns in upbeat PhII data in COPD; VIVUS advances FDA app for ED drug;

@FierceBiotech: Synageva inks orphan drug R&D deal with Mitsubishi Tanabe Pharma, grabs $3M upfront News | Follow @FierceBiotech

@JohnCFierce: Oxigene says it still can't raise cash, has to lay off more people. Going, going.... Report | Follow @JohnCFierce

@RyanMFierce: Would the extra 60-day filing period for FDA reviews of new drugs actually bring the treatments to market sooner? | Follow @RyanMFierce

> Pearl Therapeutics has turned in some positive results from a Phase IIb dose-ranging trial for its inhaled COPD drug formoterol fumarate, providing more safety and efficacy data on the treatment in anticipation of Phase III development slated to start late next year. Pearl release

> Tokyo-based drug company Eisai is dropping development of extended-release Pariet/AcipHex after the FDA handed the company a complete response letter on its application for approval of the treatment in February. Announcement

> VIVUS ($VVUS) reports that the FDA has accepted its NDA for its erectile-dysfunction drug avanafil. Regulators are expected to decide whether to clear the drug for the market by Apr. 29, 2012. Item

> Repligen ($RPEN) is working on an application for FDA approval of a hormone-based drug for improving MRI scans of the pancreas in hopes of becoming known for its commercial chops. Article

Pharma News

@FiercePharma: Tarceva's new European OK points up Roche's targeted goals. Item | Follow @FiercePharma

> More eye patients go blind after Avastin injections. Report

> Family owners eye bids for Italy's Rottapharm. Story

> Thanks to German pricing, Lilly, BI forego Trajenta launch. Article

> Lilly in partnership talks with Turkey's MN Pharma. Piece

And Finally... Xconomy is asking folks to vote on what brand of bad news companies will try to slip onto the wires after the market closes today, on the last business day before Labor Day. (My vote: pharma partnership collapses). Poll

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.